We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Share Name | Share Symbol | Market | Type | Share ISIN | Share Description |
---|---|---|---|---|---|
Renovo Grp | LSE:RNVO | London | Ordinary Share | GB00B081NX89 | ORD 10P |
Price Change | % Change | Share Price | Bid Price | Offer Price | High Price | Low Price | Open Price | Shares Traded | Last Trade | |
---|---|---|---|---|---|---|---|---|---|---|
0.00 | 0.00% | 15.625 | - | 0.00 | 00:00:00 |
Industry Sector | Turnover | Profit | EPS - Basic | PE Ratio | Market Cap |
---|---|---|---|---|---|
0 | 0 | N/A | 0 |
Date | Subject | Author | Discuss |
---|---|---|---|
17/6/2011 12:16 | I was thinking about a split but that wont work either, I guess no matter how this is done there will be consequences for others. Im sitting on a loss on this one so will just offset that against some of my other gains. Ditto with a dividend, dont know how the SB would get on though, do you get paid dividends through a spread bet long ? | smith99 | |
17/6/2011 11:49 | and then you pay tax on it..... | jebenn1 | |
17/6/2011 11:07 | cash is like 16.6p so a easy guaranteed 20% profit + keep the other stuff going, and if we hit big on either great upside, great job, or keep your money in bank for 20 years to get same cash back on interest :) a no brainer this is. | daytraders | |
17/6/2011 10:47 | 'People are here for the quick profit on cash not the IP, IMO' you'll get your cash level, since if RNVO either pays out 16p/share or buys back the equivalent shares, the share price will get to that level. | the_doctor | |
17/6/2011 10:41 | GS - as Doc said, changing to AIM will not impact any SB positions at all. Also I wouldn't worry about people 'dumping' if it gets to 16p, because if you think about it anytime it is below that there should arguably be a buyer because it is trading below the intrinsic value of the cash to be distributed. It's self-fulfilling in short, for anyone that jumps out, if the price goes down you would expect someone else to come in and push it back up. On another note, I'm currently researching Lipoxen, and E-Therapeutics, anyone here hold either? | holly_dog | |
17/6/2011 10:00 | 1. it isnt an indefinite time frame, it'd be value added through data updated and deals over a year or so 2. the benefit from holding would be a risk-free chance of this upside why buy at above the cash level in the first place if just going to sell when it returns to that level?? what did people expect? | the_doctor | |
17/6/2011 09:14 | cumnor, I dont see why they'd need to Gartmore potentially gets say 16p cash then a holding in a shell that could provided 1-20p gains later if trial results are positive and products are sold the plan gives shareholders the best of both worlds: - near-term return of cash - longer-term chance of bigger gains from products than if they were sold for peanuts now | the_doctor | |
17/6/2011 08:37 | Doc, I suspect the likes of Gartmore are not here just for cash and the relative rerating of other assets versus our cash might prompt them to rethink and perhaps make an acquisition. As you say we have the ip and trials as well which makes it more interesting. | cumnor | |
17/6/2011 08:34 | Could there be any danger from the unvested options? I don't know what would be the strike price but could affect the numbers. | ladyfarmer | |
17/6/2011 08:30 | smith the beauty of distributing cash/buying back shares is that holders get the cash back now (zero risk) PLUS then a chance for more upside later if the products perform. At this level, I see it as pure upside, but I guess if some see the upside as minimal or unlikely, they may not care. It's still possible that Gartmore will have other aims, but I suspect they aim to get everything back on the new shares, plus the sort of risk-free upside I refer to | the_doctor | |
17/6/2011 08:23 | Agree, Holly, Rnvo share price collapse was just down to bad luck and the management team have always been excellent and honest. imo | cumnor | |
17/6/2011 08:20 | While I think rnvo will always be a sore spot for the failed Juvista trial, you can't fault the mgt team at all. obviously this is what they are paid to do (and paid well mind) but totally agree cumnor, they deserve credit for how they have handled this | holly_dog | |
17/6/2011 08:07 | JB, it shows the value the city attributes to aim in general-a negative one and why shorting is now the new norm. It's a lesson for anyone thinking of investing in aim and as a market place it should be avoided at al costs. It is only thus the small City firms/advisors/corru | cumnor | |
17/6/2011 08:01 | Doc, I think from an PI point of view, cash now so that I can draw a line under it and something, maybe for the future suits me more than waiting for another 12 months for trials to conclude, Its amazing how funds could leak over that 12 month period. I appreciate what you say about II though. | smith99 | |
17/6/2011 07:55 | I bought into this as a safe bet for my cash circa 15p-15.5 avg several months back and now i am glad I did. Unusual for an aim company to do exactly as it said it would and is a credit to the Prof. Given how the market and aim in particular has performed since this has been a wise investment, although no major deals, take out occured. Unlike the mgmts of many aim companies winding up Mgt have watched money, controlled costs and the involvement of a couple of big funds is very positive as they will ensure this will be the case and yet the potential remains for a merger/to given how the value of some really good aim companies with real assets have collapsed, thus in effect doubling what you can now get for money. The IP and anticipated trials, in effect paid for, are worth a few million and much more if they surprise. So i am happy, esp given the collapse of Aim, and would'nt be surprised to see new directors/investors take advantage of the cash pile while companies are cheap. I would be happy with that, esp as you can trust mgmt, a rare thing on aim. Given the impossibility for small companies to raise cash at present, either from banks or investors, 33ml cash, ip, a listing, ownership of a few clinical trials, minimal cash burn and a mgmt team with flair you can trust is worth a lot more than 14p per share. Happy to hold. imo | cumnor | |
17/6/2011 07:39 | Incredible not many takers for the cash even in this dire market? | joeblogg2 | |
17/6/2011 07:14 | I don't think people will be pricing it up so i can trade in and out! mgt have stated they are likely to do as you say, so the price will move to reflect the cash balance of 16.8p whether through buy back or distribution to shareholders. Then i'm sure there will be some who won't want to wait for results and will sell out, will others will sit tight. nothing wrong with either strategy | holly_dog | |
17/6/2011 06:59 | well holly_dog, why should people price it up to 17p just so you can trade in/out at their expense? that'll only happen if shareholders on the list at a certain time get say 16p cash returned or sufficient shares are bought back in the right way. That could be via an offer for stock at 16p for example | the_doctor | |
17/6/2011 06:56 | Time value of money would be my reason. The price will be flat until next results after cash and I can easily move in and out so plan to do so. For an institution no such luck though as their holdings too large to easily shift in and out. Gartmore will ultimately have strong say now and that is great for shareholders - I think wider community will be v pleased with their appointment | holly_dog | |
17/6/2011 06:49 | smith99 - wouldnt make sense to an inst. Why sell at 16p when you're very likely to get something from the products? | the_doctor |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions